It’s the best explanation for what we are witnessing, in my books, but watch my new video edit and make up your own mind.
And if he has attempted this, then the WEF has just shot one of its own kneecaps.

The Canadian Opportunity – Trudeau’s full speech at Davos 2016
“Justin is just a WEF mouthpiece” – Trudeau’s own half-brother
Trudeau’s half-brother sounds like his polar opposite, this sh!t is out of Lucas Films

BONUS: full LIST OF CANADIAN wef YOUNG GLOBAL LEADERS

Compiled from YGL’s own website:

Almost all of them…

The list only covers YGL in its current shape and form, from 2004 onwards. The community evolved on the shoulders of older Klaus Schwab projects that have continuity in YGL but aren’t covered here. Learn more here:
KLAUS SCHWAB’S YOUTH IS CALLED “YOUNG GLOBAL LEADERS”, READY FOR REGIME CHANGE IN UNALIGNED COUNTRIES

Chrystia Freeland

Deputy Prime Minister and Minister of Finance, Office of the Deputy Prime Minister of Canada, Canada

WEF profile

YGL profile

Sean Fraser

Ministry of Immigration, Refugees and Citizenship, Citizenship and Immigration Canada, Canada

François-Philippe Champagne

Minister of Innovation, Science and Industry, Innovation, Science and Economic Development Canada, Canada

Elissa Golberg

Assistant Deputy Minister for Strategic Policy, Global Affairs Canada, Canada

Karina Gould

Minister of Families, Children and Social Development, Employment and Social Development Canada, Canada

Renée Maria Tremblay

Senior Counsel, Supreme Court of Canada, Canada

Jagmeet Singh

Leader, Canada’s New Democrats, New Democratic Party of Canada, Canada

Kim Hallwood

Head of Corporate Sustainability, HSBC Bank Canada, Canada

Brett House

Deputy Chief Economist, Scotiabank, Canada

Catherine Raw

CHIEF OPERATING OFFICER, NORTH AMERICA, Barrick Gold Corporation, Canada

Jocelyn Formsma

Executive Director, National Association of Friendship Centres, Canada

Joelle Faulkner

President and Chief Executive Officer, Area One Farms, Canada

Ailish Campbell

Ambassador of Canada to the European Union, Global Affairs Canada, Canada

Jessica Burgner-Kahrs

Associate Professor, University of Toronto Mississauga, Canada

Scott Brison

Vice-Chair, Investment & Corporate Banking, BMO Financial Group, Canada

Tony Abrahams

Co-Founder and Chief Executive Officer, Ai-Media, Canada

Khaled Al Sabawi

Founder and Chief Executive Officer, Open Screenplay, Canada

Jennifer Corriero

Co-Founder and Executive Director, TakingITGlobal, Canada

Jean-François Gagné

VP AI, Canada

Nathaniel Harding

Managing Partner, Cortado Ventures, USA

Vera Kobalia

Co-Founder, Olyn, Canada

Michele Romanow

Co-Founder and President, Clear Finance Technology Inc – Clearbanc, Canada

Maya Roy

Chief Executive Officer, YWCA Canada, Canada

Liam Sobey

Vice-President, Merchandising, Sobeys Inc., Canada

Ilona Szabó de Carvalho

President, Igarape Institute, Canada

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

We warned you that giving these people free access to your body is a bad idea, for they will take advantage to put in and take out all sorts of things you don’t know about. Just like they do with everything else.

If you’ve been around for a while, this doesn’t really surprise you, but it’s a valuable confirmation and we can move over with this discussion.

If not, you definitely need to catch up with this too:

BGI – BILL GATES’ & BIG TECH’S CHINESE DARLINGS: WORLD’S TOP DNA HARVESTERS, CLONERS, UIGHUR PERSECUTERS (BIOHACKING P.4)

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

The Internets got agitated recently at the news that Moderna’s CEO, Stephane Bancel, dumped $400Million in Moderna stocks and nuked his Twitter account. Here’s why this shouldn’t surprise you and you should expect the worst any moment now.

Developing story, to be updated

Have you watched the former Blackrock director that went on Bannon’s War Room and prophesied that the Covid vaccines are a bubble that’s about to pop? Everything I’ve learned lately stands to support his claim.

This is him on Twitter:

If the dumping were a sudden and unusual move, this would indicate a recent event that shook the system, possibly rats leaving a sinking ship, a near threat for the business, as in:

That’s the case only partly, due to the stock crash overlapped with the incoming financial report, but a constant behavior over the span of months and years rather indicate a strategy and it’s associated with insider trading more often than not.

Surprisingly, it’s NPR of all the fakestream media who came in support of my suspicions, with a pretty merciless analysis of Moderna’s leadership financial behavior. And you know what’s funny? The piece dates all the way back to September 2020. I recommend reading the whole piece, I added the bolding and highlights :

Whether the coronavirus vaccine developed by Moderna succeeds or not, executives at the small biotech company have already made tens of millions of dollars by cashing in their stock. An NPR examination of official company disclosures has revealed additional irregularities and potential warning signs.

“On a scale of one to 10, one being less concerned and 10 being the most concerned,” said Daniel Taylor, an associate professor of accounting at the Wharton School, “this is an 11.”

Taylor said Moderna’s stock-selling practices appear well outside the norm, and raise questions about the company’s internal controls to prevent insider trading.

Since January, CEO Stéphane Bancel has sold roughly $40 million worth of Moderna stock held by himself or associated investment funds; Chief Medical Officer Tal Zaks has sold around $60 million; and President Stephen Hoge has sold more than $10 million.

Stéphane Bancel, chief executive officer of Moderna, has sold roughly $40 million worth of stock in the company since the beginning of this year.

The stock sales first came to widespread notice after Moderna announced positive early data from a vaccine trial in May [2020 – S.m.]. At that point, the company’s share price jumped and official disclosures showed executives cashing in their shares for millions of dollars.

“As long as stocks are sold after public announcements – and not before – one might conclude that for an executive with significant net worth tied up in the company, it’s a prudent thing to do,” said Marc Fagel, a former longtime enforcement official with the Securities And Exchange Commission (SEC). “But the optics aren’t great.”

The Moderna vaccine was quick to reach a phase 3 trial, and is seen as a promising contender. But, in some ways, the executives’ stock sales have overshadowed the company’s progress.

Advocates have questioned whether it’s appropriate for executives to privately profit before bringing the vaccine to market, especially when American taxpayers have committed roughly $2.5 billion to the company’s vaccine development and manufacture.

Here’s what NPR’s examination found:

  • Stock Sales Worth Tens Of Millions: Since June 1, NPR has found, company executives have sold roughly $90 million worth of Moderna stock. Rather than put a hold on the trades after facing intense criticism in May, company executives continued to sell.
  • Questionable Modifications To Stock Sale Plans: Moderna says its executives pre-scheduled their stock sales long in advance. Those schedules – known as 10b5-1 plans – can act as a defense to charges of insider trading. But the plans have to be put in place when executives do not have confidential inside information. NPR has found multiple executives adopted or modified their plans just before key announcements about the company’s vaccine. That has raised questions about whether they were aware of nonpublic information when they planned their stock trades.
  • Selling To Zero: Generally, corporate best practices suggest that a company’s leadership should hold on to at least some stock in their company to have “skin in the game.” That way, the thinking goes, an executive has an incentive to improve the company’s performance. As Moderna has been developing its coronavirus vaccine, two executives, including the Chief Medical Officer, have sold all their stock holdings in the company. The General Counsel has sold nearly all of her holdings.

In an interview with NPR, Ray Jordan, Moderna’s Chief Corporate Affairs Officer, said the company has strict internal policies in place to prevent illegal insider trading. For example, Jordan said, the company only allows employees to make changes to their stock sale schedules when they don’t have confidential inside information that could affect the company’s share price.

NPR asked Jordan why Moderna executives modified their 10b5-1 plans just before major announcements. Initially, Jordan said by email, “I believe you must have your dates wrong.”

NPR then provided documentation of those dates from the company’s official disclosures to the government, which Jordan did not dispute.

Jordan then said that even though multiple Moderna executives changed their 10b5-1 plans within one business day of announcements, the company had determined that those executives did not have “material nonpublic information” – a key term for insider trading – when they made those changes.

A spokesperson for the SEC declined to comment for this story.

From a relative unknown, to a key player in the vaccine race

Moderna launched in 2010 with a headquarters based in Cambridge, Mass., focused on using a technology called messenger RNA (or mRNA) to develop vaccines and therapeutics. The mRNA technology has been widely considered innovative, but remains largely unproven. The company has never brought a product to market. In early January, Moderna was trading for under $20 per share, and was valued at around six billion dollars.

Then Moderna announced that it had started collaborating on a coronavirus vaccine with scientists from the National Institute of Allergy and Infectious Diseases, which is led by Dr. Anthony Fauci.

By April, the government had committed half a billion dollars to the Moderna vaccine project as part of Operation Warp Speed.

Since then, the company’s stock price has exploded. Press releases suggesting positive news from the scientific trials, or announcing additional commitments of taxpayer funding sent the share price to a peak of around $95, before dropping to between $60-$70 in recent months. The company is now valued at around $25 billion.

As a result, shares owned by Moderna executives suddenly became much more valuable. And those executives have cashed in tens of millions of dollars worth of stock, according to filings with the SEC.

The bad press and critical comments did not deter continued sales. Since June 1, NPR found, executives sold around $90 million worth of stock.

Public money, private gain

The U.S. government is making massive financial bets on several vaccine candidates. In all likelihood, only some of those vaccine candidates will prove sufficiently safe and effective.

“If the vaccine doesn’t work, you lost a lot of money,” Fauci has said. “But we feel this is serious enough that it’s worth the financial risk.”

But even if taxpayers lose money betting on Moderna, the company’s executives have already made millions.

“The insiders are making plenty of profit and they’re mostly doing it with our money,” said Margarida Jorge, a campaign director with the group Lower Drug Prices Now. “I’m absolutely for deploying public money in the interests of public health and the public good. But we don’t have any commitment from the administration that any of this investment is ultimately going to benefit real people.”

Moderna has argued that the company was only in a position to work with the government on a coronavirus vaccine, because it had spent a decade developing its mRNA technology with the support of private investors.

“The company has been funded over the years by billions of dollars of private investment,” Zaks told the Freakonomics podcast in August. “Those billions created the opportunity for the U.S. government to come in earlier this year and say, ‘I’m going to add some money to the pot to make sure that you get the development for this vaccine right.'”

[But they locked in the Government and its funding for mRNA technology years before SARS-COV2, as shown below, so this was a deliberate lie – S.m]
Trying to resuscitate the company with some archive work?

“Set it and forget it” stock plans

Moderna has offered another defense of those stock sales: the sales, representatives and executives say, were scheduled well in advance, and were unrelated to the market-moving announcements about the coronavirus vaccine. An NPR examination of the company’s financial filings tells a more complicated story.

The schedules are known as 10b5-1 plans. If your stock trades are on autopilot, the idea goes, then you can’t be accused of insider trading. But these “set it and forget it” plans have to be adopted when executives do not have “material nonpublic information,” to use the legal term.

In an interview with CNBC in July, CEO Bancel said he and other executives set up their 10b5-1 plans “a long time ago” – in December 2018 – and “obviously, when we set up those plans, none of us had any idea what was going to happen in 2020.”

In fact, NPR has found, Moderna executives, including Bancel himself, implemented new plans or modified older plans at multiple points in 2020, and right around key announcements related to the company’s vaccine.

On Jan. 21, 2020, for example, Chief Medical Officer Dr. Tal Zaks amended his 10b5-1 plan. (It’s unclear what changes he made.)

Then, on Jan. 22, Moderna first widely confirmed that it was working with the government on a coronavirus vaccine. The following day, Jan. 23, the company announced it had received additional funding to support its coronavirus vaccine development.

NPR asked Moderna whether Zaks might have been aware of the collaboration with the government when he changed his stock trading plan.

“What was known on that particular day or not known, I couldn’t specifically talk to,” Moderna’s Jordan told NPR. But he said that the Moderna legal team only allows employees to change their 10b5-1 plans if they do not possess inside information that could affect the company’s share price.

Later, on Friday, March 13, three Moderna executives adopted new 10b5-1 plans, according to records reviewed by NPR: Zaks, Chief Technical Operations and Quality Officer Juan Andres, and then-Chief Financial Officer Lorence H. Kim. (Kim left the company in August 2020.)

On Monday, March 16 – one business day later – the company announced that it had given a participant the first dose of their vaccine as part of its phase 1 trial. The stock ended that day up 24% compared to the previous day’s close. Moderna was “bucking the trend” of the broader market, which was panicking over coronavirus fears, one CNBC host said at the time.

Timing Of Changes To Pre-Scheduled Stock Sales Raises Questions

Jan. 21 – Chief Medical Officer Dr. Tal Zaks amends his schedule of stock sales, known as a 10b5-1 plan.

Jan. 22 – Moderna widely confirms that it is working on a coronavirus vaccine with the National Institutes of Health. The company’s share price rises nearly 5% over the previous day’s close.

Jan. 23 – Moderna announces new funding from the Coalition for Epidemic Preparedness Innovations.

Mar. 13 – Chief Technical Operations Officer Juan Andres, Chief Financial Officer Lorence Kim, and Zaks adopt new 10b5-1 trading plans.

Mar. 16 – Moderna announces that it provided the first dose of its coronavirus vaccine to a participant in a phase 1 trial. Moderna stock climbs 24% over the previous day’s close.

May 18 – Moderna reports early positive data from its phase 1 trial. The company’s stock ends the day up 20% over the previous day’s close.

May 21 – CEO Stéphane Bancel adopts and amends multiple 10b5-1 trading plans.

May 29 – Moderna announces another milestone in its phase 2 coronavirus vaccine trial.

June 1 – President Stephen Hoge amends his 10b5-1 plan.

Despite the close timing, Jordan told NPR, “by the judgment of the legal team, there would not have been material, nonpublic information known” when executives entered into the new plans.

“Every company and individual is entitled to the presumption of innocence. That said, from the public’s perspective, this trading behavior looks very problematic,” said Taylor of the Wharton School, who first pointed out the timing of these changes to NPR.

“If I put on my SEC enforcement hat, I would certainly be asking, ‘What caused you to change the plan on a Friday?'” said Kurt Wolfe, who works as a defense attorney in securities cases for the firm Troutman Pepper. “I don’t think it’s a good fact pattern.”

On May 21 – in between announcements of major vaccine trial milestones on May 18 and May 29 – CEO Bancel amended and adopted 10b5-1 plans. And on June 1, President Hoge amended his trading plan.

“Amending a trading plan after a positive announcement, like trading after a positive announcement, is only problematic if the executive possesses material, nonpublic information at the time,” said Fagel. “Though repeated or questionably-timed changes to a trading plan will reduce its value as a defense to insider trading.”

Selling to zero

Using these 10b5-1 plans, two Moderna executives – Zaks and Andres – have sold all of their shares in the company. General Counsel Lori Henderson has sold nearly all of her shares.

In fact, roughly every week since June, Zaks has exercised stock options (meaning, he bought stock at a price set by the company as part of his compensation), and then immediately sold all of his shares for a significant profit.

[Isn’t this a great explanation for Bancel’s sales too?! – S.m]


On Aug. 24, for example, Zaks exercised stock options and bought 25,000 shares at bargain prices of between $12 to $21. He then immediately sold all of those shares for around $65 per share. Zaks ended up with a profit of nearly $1.2 million.

SEC filings indicate these trades are made under the 10b5-1 plan he adopted in March.

Selling so much stock can also raise concerns for investors – and the public – about why company leaders would sell now if they expected their vaccine to succeed later. After all, a safe and effective vaccine could send Moderna’s stock to even greater heights.

“It perhaps draws questions about how much they believe in it,” said Wolfe.

If the company does develop a safe and effective coronavirus vaccine, and its stock keeps rising, then “these trades will be water under the bridge,” said Fagel, the former SEC enforcement official.

But, Fagel warns, if the vaccine fails, then SEC regulators and angry investors may come looking for answers. In that case, he said, “both class action litigation and an SEC investigation would seem inevitable.”

NPR revelations end here, we’re actually just starting

So what we’ve learned is that Moderna looks like a stock market operation more than a medical one. The chiefs create momentums and then trade. And they use public money to bet and make billions, but more about that shortly.

This news is actually pretext to get you to know the real history of Moderna, a crux point in modern history in the widest sense. The stock dumping is not really news, it’s been happening for quite a while, indicating a long term strategy and business model, rather than a sudden or impulse move.

The next two older reports from Pharma’s own media – STAT, will cement the certainty that Moderna turned into a stock market bubble long ago, under the helms of Stephan Bancel. They don’t mind having some science to show, but that’s just the bait.

Ego, ambition, and turmoil: Inside one of biotech’s most secretive startups

By Damian Garde for STAT, Sept. 13, 2016

At first glance, Moderna Therapeutics looks like the most enviable biotech startup in the world. It has smashed fundraising records and teamed up with pharmaceutical giants as it pursues a radical plan to revolutionize medicine by transforming human cells into drug factories.

But the reality is more complicated.

A STAT investigation found that the company’s caustic work environment has for years driven away top talent and that behind its obsession with secrecy, there are signs Moderna has run into roadblocks with its most ambitious projects.

At the center of it all is Stéphane Bancel, a first-time biotech CEO with an unwavering belief that Moderna’s science will work — and that employees who don’t “live the mission” have no place in the company. Confident and intense, Bancel told STAT that Moderna’s science is on track and, when it is finally made public, that it will meet the brash goal he himself has set: The new drugs will change the world.

But interviews with more than 20 current and former employees and associates suggest Bancel has hampered progress at Moderna because of his ego, his need to assert control and his impatience with the setbacks that are an inevitable part of scienceModerna is worth more than any other private biotech in the US, and former employees said they felt that Bancel prized the company’s ever-increasing valuation, now approaching $5 billion, over its science.

As he pursued a complex and risky strategy for drug development, Bancel built a culture of recrimination at Moderna, former employees said. Failed experiments have been met with reprimands and even on-the-spot firings. They recalled abusive emails, dressings down at company meetings, exceedingly long hours, and unexplained terminations.

At least a dozen highly placed executives have quit in the past four years, including heads of finance, technology, manufacturing, and science. In just the past 12 months, respected leaders of Moderna’s cancer and rare disease programs both resigned, even though the company’s remarkable fundraising had put ample resources at their disposal. Each had been at the company less than 18 months, and the positions have yet to be filled.

Lower-ranking employees, meanwhile, said they’ve been disappointed and confused by Moderna’s pivot to less ambitious — and less transformative — treatments. Moderna has pushed off projects meant to upend the drug industry to focus first on the less daunting (and most likely, far less lucrative) field of vaccines — though it is years behind competitors in that arena.

The company has published no data supporting its vaunted technology, and it’s so secretive that some job candidates have to sign nondisclosure agreements before they come in to interview. Outside venture capitalists said Moderna has so many investors clamoring to get in that it can afford to turn away any who ask too many questions. Some small players have been given only a peek at Moderna’s data before committing millions to the company, according to people familiar with the matter.

“It’s a case of the emperor’s new clothes,” said a former Moderna scientist. “They’re running an investment firm, and then hopefully it also develops a drug that’s successful.”

Like many employees and former employees, the scientist requested anonymity because of a nondisclosure agreement. Others would not permit their names to be published out of fear that speaking candidly about big players in the industry would hurt their job prospects down the road.

Moderna just moved its first two potential treatments — both vaccines — into human trials. In keeping with the culture of secrecy, though, executives won’t say which diseases the vaccines target, and they have not listed the studies on the public federal registry, ClinicalTrials.gov. Listing is optional for Phase 1 trials, which are meant to determine if a drug is safe, but most companies voluntarily disclose their work.

Investors say it’ll be worth the wait when the company finally lifts the veil.

“We think that when the world does get to see Moderna, they’re going to see something far larger in its scope than anybody’s seen before,” said Peter Kolchinsky, whose RA Capital Management owns a stake in the company.

Moderna
The Moderna offices in Cambridge, Mass.ARAM BOGHOSIAN FOR STAT

Bancel, meanwhile, said he is aware of the criticism of him and has taken some steps to address it. After scathing anonymous comments about Moderna’s management began showing up online, Bancel went to Silicon Valley to get tips on employee retention from the human resources departments of Facebook, Google, and Netflix. But he makes no apologies for tumult past or present, pointing to the thousands of patients who might be saved by Moderna’s technology.

“You want to be the guy who’s going to fail them? I don’t,” he said in an interview from his glassy third-floor office. “So was it an intense place? It was. And do I feel sorry about it? No.”

An ambitious CEO dreams big

Bancel, 44, had no experience running a drug development operation when one of biotech’s most successful venture capitalists tapped him to lead Moderna. He’d spent most of his career in sales and operations, not science.

But he had made no secret of his ambition.

A native of France, Bancel earned a master’s in chemical engineering from the University of Minnesota and an MBA from Harvard in 2000. As Harvard Business School classmates rushed to cash in on the dot-com boom, Bancel laid out a plan to play “chess, not checkers.”

“I was always thinking, one day, somebody will have to make a decision about me getting a CEO job,” he told an audience at his alma mater in April. “… How do I make sure I’m not the bridesmaid? How do I make sure that I’m not always the person who’s almost selected but doesn’t get the role?”

He went into sales and rose through the operational ranks at pharmaceutical giant Eli Lilly, eventually leading the company’s Belgian operation. And in 2007, at just 34, he achieved his goal, stepping in as CEO of the French diagnostics firm bioMérieux, which employs roughly 6,000 people.

The company improved its margins under Bancel’s tenure, and he developed a reputation as a stern manager who got results, according to an equities analyst who covered bioMérieux at the time.

“He doesn’t suffer fools lightly,” the analyst said, speaking on condition of anonymity to comply with company policy. “I think if you’re underperforming, you’ll probably find yourself looking for another job.”

Bancel’s rise caught the eye of the biotech investment firm Flagship Ventures, based here in Cambridge. Flagship CEO Noubar Afeyan repeatedly tried to entice him to take over one of the firm’s many startups, Bancel said. But he rejected one prospect after another because the startups seemed too narrow in scope.

Moderna was different.

The company’s core idea was seductively simple: cut out the middleman in biotech.

For decades, companies have endeavored to craft better and better protein therapies, leading to new treatments for cancer, autoimmune disorders, and rare diseases. Such therapies are costly to produce and have many limitations, but they’ve given rise to a multibillion-dollar industry. The anti-inflammatory Humira, the world’s top drug at $14 billion in sales a year, is a shining example of protein therapy.

Moderna’s technology promised to subvert the whole field, creating therapeutic proteins inside the body instead of in manufacturing plants. The key: harnessing messenger RNA, or mRNA.

In nature, mRNA molecules function like recipe books, directing cellular machinery to make specific proteins. Moderna believes it can play that system to its advantage by using synthetic mRNA to compel cells to produce whichever proteins it chooses. In effect, the mRNA would turn cells into tiny drug factories.

It’s highly risky. Big pharma companies had tried similar work and abandoned it because it’s exceedingly hard to get RNA into cells without triggering nasty side effects. But if Moderna can get it to work, the process could be used to treat scores of diseases, including cancers and rare diseases that can be death sentences for children.

Bancel was intrigued. He knew it was a gamble, he told STAT, “but if I don’t do it, and it works, I’m just going to kick myself every morning.”

And so he became the company’s CEO — and soon developed an almost messianic reverence for the mRNA technology.

Despite having never worked with RNA before, Bancel said he sat around the table with his core team in the early days of the company, dreaming up experiments. As a result, he is listed as a co-inventor on more than 100 of Moderna’s early patent applications, unusual for a CEO who is not a PhD scientist.

Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine

By Damian Garde, STAT, Jan. 10, 2017

SAN FRANCISCO — Moderna Therapeutics, the most highly valued private company in biotech, has run into troubling safety problems with its most ambitious therapy, STAT has learned — and is now banking on a mysterious new technology to keep afloat its brash promise of reinventing modern medicine.

Exactly one year ago, Moderna CEO Stéphane Bancel talked up his company’s “unbelievable” future before a standing-room-only crowd at the annual J.P. Morgan Healthcare Conference here. He promised that Moderna’s treatment for a rare and debilitating disease known as Crigler-Najjar syndrome, developed alongside biotech giant Alexion Pharmaceuticals, would enter human trials in 2016.

It was to be the first therapy using audacious new technology that Bancel promised would yield dozens of drugs in the coming decade.

But the Crigler-Najjar treatment has been indefinitely delayed, an Alexion spokeswoman told STAT. It never proved safe enough to test in humans, according to several former Moderna employees and collaborators who worked closely on the project. Unable to press forward with that technology, Moderna has had to focus instead on developing a handful of vaccines, turning to a less lucrative field that might not justify the company’s nearly $5 billion valuation.

“It’s all vaccines right now, and vaccines are a loss-leader,” said one former Moderna manager. “Moderna right now is a multibillion-dollar vaccines company, and I don’t see how that holds up.”

Bancel made no mention of the Crigler-Najjar drug when he spoke Monday before a similarly packed room at this year’s J.P. Morgan conference.

His presentation instead focused on four vaccines that the company is moving through the first phase of clinical trials: two target strains of influenza, a third is for Zika virus, and the fourth remains a secret. Bancel clicked through graphs of data from animal studies before hurrying on to tout Moderna’s balance sheet and discuss the company’s cancer vaccines, slated for clinical testing later this year.

When STAT asked Bancel after the presentation about Crigler-Najjar, he deferred to Alexion.

In need of a Hail Mary

Founded in 2012, Moderna reached unicorn status — a $1 billion valuation — in just two years, faster than Uber, Dropbox, and Lyft, according to CB Insights. The company’s premise: Using custom-built strands of messenger RNA, known as mRNA, it aims to turn the body’s cells into ad hoc drug factories, compelling them to produce the proteins needed to treat a wide variety of diseases.

But mRNA is a tricky technology. Several major pharmaceutical companies have tried and abandoned the idea, struggling to get mRNA into cells without triggering nasty side effects.

Bancel has repeatedly promised that Moderna’s new therapies will change the world, but the company has refused to publish any data on its mRNA vehicles, sparking skepticism from some scientists and a chiding from the editors of Nature.

The indefinite delay on the Crigler-Najjar project signals persistent and troubling safety concerns for any mRNA treatment that needs to be delivered in multiple doses, covering almost everything that isn’t a vaccine, former employees and collaborators said.

The company did disclose a new technology on Monday that it says will more safely deliver mRNA. It’s called V1GL. Last month, Bancel told Forbes about another new technology, N1GL.

But in neither case has the company provided any details. And that lack of specificity has inevitably raised questions.

Three former employees and collaborators close to the process said Moderna was always toiling away on new delivery technologies in hopes of hitting on something safer than what it had. (Even Bancel has acknowledged, in an interview with Forbes, that the delivery method used in Moderna’s first vaccines “was not very good.”)

Are N1GL and V1GL better? The company has produced no data to answer that question. When STAT asked about new technologies, Bancel referred questions to the company’s patent filings.

The three former employees and collaborators said they believe N1GL and V1GL are either very recent discoveries, just in the earliest stages of testing — or else new names slapped on technologies Moderna has owned for years.

“[The technology] would have to be a miraculous, Hail Mary sort of save for them to get to where they need to be on their timelines,” one former employee said. “Either [Bancel] is extremely confident that it’s going to work, or he’s getting kind of jittery that with a lack of progress he needs to put something out there.”

Former employees and collaborators who spoke with STAT requested anonymity because they had signed nondisclosure agreements — which the highly secretive Moderna requires even some job candidates to sign.

STAT investigation last year found that Bancel had driven away top talent from Moderna with a culture of recrimination and a caustic work environment, including on-the-spot firings for failed experiments.

The company, based in Cambridge, Mass., seems to have repaired its reputation among many rank-and-file employees, winning workplace accolades from Science Magazine and the Boston Globe, but Moderna has lost more than a dozen top scientists and managers in the past four years, despite its vast financial resources.

A bug in the software

Bancel, a first-time biotech CEO, has dismissed questions about Moderna’s potential. He describes mRNA as a simple way to develop treatments for scores of ailments. As he told STAT over the summer, “mRNA is like software: You can just turn the crank and get a lot of products going into development.”

Related: SOFTWARE OF LIFE™ IS A MODERNA TRADE MARK FOR MRNA. LITERALLY. AND THEY MAKE APPS

It seems clear, however, that the software has run into bugs.

Patients with Crigler-Najjar are missing a key liver enzyme needed to break down bilirubin, a yellowish substance that crops up in the body as old red blood cells break down. Without that enzyme, bilirubin proliferates in the blood, leading to jaundice, muscle degeneration, and even brain damage.

In Moderna’s eyes, the one-in-million disease looked like an ideal candidate for mRNA therapy. The company crafted a string of mRNA that would encode for the missing enzyme, believing it had hit upon an excellent starting point to prove technology could be used to treat rare diseases.

But things gradually came apart last year.

Every drug has what’s called a therapeutic window, the scientific sweet spot where a treatment is powerful enough to have an effect on a disease but not so strong as to put patients at too much risk. For mRNA, that has proved elusive.

STAT
mRNA jabs are “rewriting the Genetic Code” we call it “information therapy” – Tal Zaks (Ted 2017)

Before COVID-19, the company’s secretive nature, and its failure to deliver a functional product, was drawing comparisons to the infamous biotech startup Theranos. Similar to Moderna, Theranos rarely published any peer-reviewed material. Like Moderna, Theranos mastered the networking game, and recruited high profile individuals to its board in order to vouch for the company’s “revolutionary technologies.” Once valued at well over $10 Billion, Theranos collapsed after it was revealed that the company was running a massive fraud scheme, in addition to its failure to implement its promised blood testing technology.

Jordan Schachtel @JordanSchachtelIn 2015, Dr John Ioannidis published a paper calling attention to Theranos & the shady biotech unicorn industry. Moderna is mentioned as a company that is following the Theranos path of zero disclosures, & publishing zero papers on their “innovative” tech. onlinelibrary.wiley.com/doi/epdf/10.11…
April 15th 2021113 Retweets281 Likes

Moderna’s Mysterious Medicines

FORBES EDITORS’ PICK |Dec 14, 2016

Excerpts:

“Now an obscure lawsuit filed in British Columbia in October sheds light on one of Moderna’s key partners, and through it FORBES can reveal details on Moderna’s amazing but still untested technology.

It appears that the first two products Moderna has entered into clinical trials rely on technology from a small outfit in Vancouver, British Columbia, called Acuitas Therapeutics. (Acuitas is so small, in fact, that its worldwide headquarters are in its CEO’s single-family home.)

Almost all medicines either block proteins–the building blocks of life–or, in the case of expensive biotech drugs, are proteins themselves. But Moderna has been promising to hack an entirely different part of life’s cookbook. In order to turn genetic information encoded in DNA into the cellular machines that actually are proteins, living things use a messenger chemical called mRNA.

Creating these mRNA drugs is a big challenge on many levels. For them to work, Moderna needs to deliver mRNA to the body’s cells. By itself mRNA breaks down in the bloodstream. Tiny Acuitas specializes in one method: lipid-nanoparticle delivery systems. Its technology essentially wraps the mRNA into balls of fat that disguise the drug so that the target cells will readily ingest it.

“Although we are small,” says Thomas Madden, chief executive of Acuitas, “I believe the technology we have developed is highly effective.”

The problem for Madden and Moderna is that Acuitas doesn’t actually own the technology it has licensed to Moderna. The tech belongs to a third company, publicly traded Arbutus, which recently decided to terminate the license for the tech that it had granted to Acuitas. That’s why Acuitas filed the lawsuit in British Columbia, to protect the deal it had. Arbutus immediately countersued, claiming its deal with Acuitas didn’t cover Moderna’s medicines.

The legal mess has its roots in Moderna’s 2011 start, when Robert Langer, an MIT professor, Moderna board member and founder of dozens of biotech companies, told Bancel that Moderna was too underfunded and small to create its own delivery system. So Moderna vetted over a dozen external delivery methods for mRNA and settled on at least three. One belonged to Arbutus, but Moderna turned to tiny Acuitas to get access to it.

Acuitas was formed in 2009 by Madden after a merger eliminated his position at Arbutus’ predecessor, Tekmira Pharmaceuticals. After a contentious lawsuit Madden was able to license from his former employer the novel tech he had helped develop, and Bancel claims Moderna chose to work with Acuitas because it had “the people and the capabilities.”

But that doesn’t explain why Moderna–flush with capital–didn’t make sure that sublicensing through Acuitas would be okay with Arbutus before advancing its new drugs into human studies.

Bancel met with FORBES at a Brooklyn coffee shop on a recent Saturday to dispel the implications of the lawsuit. He is dismissive of Acuitas’ technology. “We knew it was not very good,” he says. “It was just okay.”

He further explains that Moderna is in the process of producing its own nanoparticle lipids. One such lipid, N1GEL (called “Nigel” internally), appears to cause less inflammation than Acuitas’ version. Another is being licensed from Merck. Bancel says Moderna has stopped using the Acuitas tech for new drugs.

That still leaves a somewhat messy situation for any Moderna vaccines that are being developed using Acuitas’ tech.

Data from one vaccine is expected early next year. If results are good, it could lead to a sizzling-hot initial public offering, even if the Canadian lawsuit ultimately affords Arbutus bigger royalty payments from Moderna.”

Well, the two tiny Canadian companies mentioned above bring royalties to the Canada’s treasury (should I say The British Crown?), so don’t expect Trudeau to backpedal too soon

AND IF ONLY THEY HUSSLED WITH PRIVATE FUNDS, AS THEY CLAIMED…

Moderna chief keep claiming that they started to use public funds only as a patch on infrastructure, science and funding they’ve built for years.

Wrong!

It’s known that NIH + NIAID have long been one of their main sources for the “lavish funding” mentioned earlier and when they locked in the government support, they actually started to leverage it and attract even more private funds, in an self-feeding loop that created today’s monster-bubble.

Very few people know they even got money from BARDA and DARPA. As in “military funds”.

Remember this lie from earlier?
“The company has been funded over the years by billions of dollars of private investment,” Zaks told the Freakonomics podcast in August. “Those billions created the opportunity for the U.S. government to come in earlier this year and say, ‘I’m going to add some money to the pot to make sure that you get the development for this vaccine right.'”
Watch this claim getting nuked:

Taken from:

This grid above looks familiar to you? It does to me, but it’s not blood from people who underwent Covid genetic therapies, just something similar. Taken from:

KEI asks DOD to investigate failure to disclose DARPA funding in Moderna patents

  by  Knowledge Ecology International (KEI)

Luis Gil Abinader has taken a deep dive into Moderna’s surprising practice of never declaring government funding in its 126 patents and 154 patent applications, despite having had funding from multiple federal agencies.

One outcome of his research is a 25 page report (RN-2020-3) on Moderna’s failure to report funding from DARPA, and a request by KEI to DOD and DARPA to remedy this, including by taking title to patents where disclosures should have been made. (Text of letter below, and PDF version here).

KEI will also send a letter to BARDA. The letter below was addressed to DOD and DARPA, and focuses on their funding.

Context

The obligation to disclose federal funding in patent applications has been subject to presidential executive orders, statutes, regulations and contracts, including those cited and quoted in Abinader’s report. The disclosure clarifies the public’s rights in the inventions and the obligations on the entity getting the money, on everything from the government’s worldwide royalty free license to the public’s march-in rights, obligations to make inventions available to the public on reasonable terms, and additional safeguards that can be exercised by a government inclined to do so.

Secondly, the disclosure changes the narrative about who has financed the inventive activity, often the most risky part of development.

One of the earlier norms on this was Franklin Roosevelt’s Executive Order 9424, on the Establishment of a Register of Government interests in patents.

In 2018, the regulations on disclosure were modified by NIST (see 83 FR 15954), where, among other things, the government gave itself unlimited time to remedy a failure to disclose federal funding, to eliminate one loophole that created an incentive ignore the disclosure requirement.

In the past, the US Department of Defense has taken title to patents where federal funding was not disclosed. See: Campbell Plastics v. Brownlee, 389 F.3d 1243 (Fed. Cir. 2004).

There is more on the broader issue of disclosure of government funding in patents here: https://www.keionline.org/bayh-dole/failure-to-disclose

The research on the Moderna/DARPA funding is outlined in a 25 page August 27, 2020 report by Luis Gil Abinader, titled: “Moderna failures to disclose DARPA funding in patented inventions.” RN-2020-3

Below is the text of the KEI letter to Dr. Mark T. Esper, Secretary of Defense, and Dr. Amy Jenkins, of the Pandemic Prevention Platform for the Defense Advanced Research Projects Agency (DARPA), regarding the apparent failure by Moderna to disclose DARPA funding in patent applications.
PDF copy here:

2020. September 18. DARPA letter to KEI confirming investigation of Moderna for failure to report government funding in patent applications. https://www.keionline.org/33970

2020. September 4. BARDA is investigating Moderna’s failures to disclose BARDA funding in patent applications. https://www.keionline.org/33907

2020. September 2. KEI request to BARDA concerning Moderna obligations to disclose federal funding in patent applications. https://www.keionline.org/33892

2020. August 30. DARPA announces investigation into Moderna’s apparent failures to disclose mRNA vaccine patents. https://www.keionline.org/33832

2020. August 28. KEI asks DOD to investigate failure to disclose DARPA funding in Moderna patents. https://www.keionline.org/33763

2020. August 27. 2020:3 KEI Research Note: Moderna failures to disclose DARPA funding in patented inventions. https://www.keionline.org/rn-2020-3

2020. August 5. BARDA Responds to KEI, Public Citizen Letter Asking BARDA to Enforce Moderna Contract. https://www.keionline.org/33633

2020. August 4. KEI and Public Citizen request BARDA to address Moderna’s noncompliance with COVID-19 vaccine contract term. https://www.keionline.org/33618

2020. July 1. KEI receives seven new contracts for COVID 19 research from BARDA and DOD, including five using “Other Transactions Authority” that weaken or eliminate Bayh-Dole and FAR Safeguards. https://www.keionline.org/covid19-ota-contracts

2020. May 21. Moderna and US Government Funding of its COVID-19 Vaccine Candidate. https://www.keionline.org/33150

MORE Press Coverage

Washington Post
2020. August 28. “Moderna failed to disclose federal support in vaccine patents, researchers say: The company with a leading coronavirus vaccine candidate did not adhere to a law designed to protect public investment.” Washington Post. Christopher Rowland.
https://www.washingtonpost.com/business/2020/08/28/moderna-vaccine-patents-darpa-funding/

Bloomberg
2020. August 29. “Moderna’s Patents Probed by U.S. Defense Department, FT Says.” Bloomberg. Chiara Vasarri. https://www.bloomberg.com/news/articles/2020-08-29/u-s-government-s-darpa-probes-patents-filed-by-moderna-ft

Axios
2020. August 5. “Moderna skirts disclosures of coronavirus vaccine costs.” Axios. Bob Herman. https://www.axios.com/moderna-barda-coronavirus-funding-disclosure-2775a517-a775-485a-a509-b6906c8535a9.html

STAT
2020. September 4. “A second U.S. agency will review if Moderna disclosed federal funding in vaccine patents.” STAT. Ed Silverman. https://www.statnews.com/pharmalot/2020/09/04/moderna-vaccine-darpa-barda-patents-covid19/

2020. August 8. “Moderna failed to disclose federal funding for vaccine patent applications, advocates say.” STAT. Ed Silverman. https://www.statnews.com/pharmalot/2020/08/28/moderna-covid19-vaccine-coronavirus-patents-darpa/

2020. August 4. “BARDA faces pressure to force Moderna to disclose cost details from its Covid-19 contract.” Ed Silverman. https://www.statnews.com/pharmalot/2020/08/04/covid19-coronavirus-pandemic-barda-moderna-vaccine-transparency/

Financial Times
2020. August 29. “US government’s Darpa probes Moderna’s vaccine patents: Researchers accuse biotech company of failing to disclose federal grants in patents which also cover Covid-19 candidate.” Financial Times. Donato Paolo Mancini. https://www.ft.com/content/2be1f87e-9e96-4e23-9cc5-33ba35e50586

National Public Radio (NPR)
2020. August 4. “Prices For COVID-19 Vaccines Are Starting To Come Into Focus.” NPR. Sydney Lupkin. https://www.statnews.com/pharmalot/2020/08/04/covid19-coronavirus-pandemic-barda-moderna-vaccine-transparency/

Health Policy Watch
2020. September 3. “US Biomedical Advanced Research & Development Agency Reviews Moderna’s US Patents For Alleged Failure To Disclose Federal Funding.” Health Policy Watch. Grace Ren.
https://healthpolicy-watch.news/pharma-watchdog-requests-further-inquiries-into-modernas-us-patents/

2020. September 1. “US Department Of Defense Is Investigating Moderna’s Patents For Allegedly Failing To Disclose Federal Support.” Health Policy Watch. Grace Ren. https://healthpolicy-watch.news/usagency-investigating-moderna-for-allegedly/

The Pharma Letter
2020. September 4. “Non-profit says Moderna hid federal funding from patent office.” The Pharma Letter. https://www.thepharmaletter.com/article/nonprofit-says-moderna-hid-federal-funding-from-patent-office

Life Sciences Intellectual Property Review
2020. September 8. “Moderna’s COVID-19 and Zika patent applications to be investigated.” Life Sciences Intellectual Property Review. Muireann Bolger. https://www.lifesciencesipreview.com/news/moderna-s-covid-19-and-zika-patent-applications-to-be-investigated-4183

Law360
2020. September 4. “HHS Unit Probes Funding For Moderna’s Patented Vaccines.” Law360. Kevin Stawicki. https://www.law360.com/articles/1307690/hhs-unit-probes-funding-for-moderna-s-patented-vaccines

2020. August 31. “DOD Investigating Moderna’s Vaccine Patents.” Law360. Kevin Stawicki. https://www.law360.com/compliance/articles/1305849/dod-investigating-moderna-s-vaccine-patents

2020. August 28. “Activists Say Moderna Hid Gov’t Support For Vaccine Patents.” Law360. Kevin Stawicki. https://www.law360.com/articles/1305474

Moderna’s vaccine was developed with support from the NIAID, and, as covered in a past fact check, analysis from Axios found that the National Institutes of Health, of which the NIAID is part, may own intellectual property used in producing Moderna’s vaccine. Dr. Francis Collins, director of NIH, has also said that NIH has a stake in intellectual property used in the vaccine, though what exactly this means in practical terms is unclear. 

The Dispatch Fact-check

Also…

All the documents Glenn Beck is creaming about and more can be found below:

Nipah virus as in…?

READ: URGENT! DEBUNKING THE NEXT ENGINEERED PANDEMIC: HEMORRHAGIC FEVER (NIPAH, MARBURG, EBOLA)

Well, yeah, no coincidence here either, more proof to that below.

SO WE HAVE A FINACIER WHO TOOK OVER A WELL FUNDED PHARMA START-UP AND BROUGHT IN HUGE FUNDS, IGNITING THE MOTHER OF ALL ENRONS. WHO’S THIS GUY?!

Buckle up, friends, this so far was jus the prelude.

Bancel came to Moderna from the French Merieux Institute.

Merieux happens to be the French billionaire who helped China build the infamous P4 Lab in Wuhan.

Merieux also happens to be an old friend of Xi’s.

That Xi visit at the Merieux HQ in France happened in 2014, not long after this:

Obama & Xi working together on a pandemic playbook in 2012

And then, in 2018..

2017

Bancel maintained a top role in the Merieux Foundation long after leaving the BioMerieux division for Moderna.

CA Merieux Foundation

Therefore no surprise that Moderna was allegedly the first to get the SARS-COV2 genetic code and start working on the mRNA injection.

CONFIDENTIAL DOCUMENTS: MODERNA SENT A MRNA CORONAVIRUS VACCINE CANDIDATE TO UNIVERSITIES WEEKS BEFORE EMERGENCE OF COVID-19

MORE COINCIDENCE THEORIES

In 2017, Moncef Slaoui, the brain behind GSK, also took a seat on the board of Moderna,

Trump awarded Moderna almost $0.5Billion from public money a few days before nominating Slaoui as Warp Speed co-chief. in May 2020.

Trump’s Moroccan “vaccine czar”: worked for Bill Gates, Google, GSK. Worked in China. Transhumanist. Lockdown fanatic

“Valera’s efforts (Moderna subsidiary) have resulted in the demonstration of preclinical efficacy of Moderna’s mRNA-based vaccines in multiple viral disease models, Moderna said.

In the partnership with the Gates Foundation, Valera will apply its mRNA vaccine platform as well as Moderna’s drug platform Messenger RNA Therapeutics™. Designed to produces human proteins, antibodies, and entirely novel protein constructs inside patient cells, the therapeutics are secreted or active intracellularly.” – Genetic Engineering & Biotechnology News

To avoid a conflict of interest, Slaoui resigned from the board of the Massachusetts-based biotech firm Moderna, which had been developing a vaccine for the coronavirus.
He stepped down but he didn’t give up his stakes in Moderna, as the Daily Beast reports:

“Slaoui’s ownership of 156,000 Moderna stock options, disclosed in required federal financial filings, sparked concerns about a conflict of interest.
Democratic Massachusetts Senator Elizabeth Warren called Slaoui out over the matter on Twitter: “It is a huge conflict of interest for the White House’s new vaccine czar to own $10 million of stock in a company receiving government funding to develop a COVID-19 vaccine. Dr. Slaoui should divest immediately.”
The company’s shares skyrocketed last month after news broke of the $483 million in federal funding to work on a coronavirus vaccine.
Slaoui could not immediately be reached for comment on the matter.”

Slaoui also sits on the boards of SutroVax, the Biotechnology Innovation Organization, the International AIDS Vaccine Initiative, and the PhRMA Foundation

Gates, Fauci and Slaoui have long been making and selling scandalous vaccines together. It’s a cartel

So we should add Bancel to this cover graphic
DAVOS 2022: BANCEL AND FAUCI MEET AGAIN TO WHINE ABOUT THE ANNOYANCE WE ARE TO THEM. MORE TO COME, SCUMBAGS!

LAST MINUTE:

The circle has just closed.
Unless China faked another interview to prop up another myth.

So this has never been about health, just a global scale racketeering operation that’s coming to light about about to go bust. You can speed up this process simply by spreading this expose far and wide!

UPDATE MARCH 21, 2022: VOILA!

Via our ex-BlackRock friend Edward Dowd. I rest my case, but I bet they will “unrest” it soon.

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

ORDER

Only days ago, Luc Montagnier was up in arms on the barricades against Covidiocracy. Suddenly, he is told to have left the battlefield, in peace, not as a fallen general.
Why such a sudden ‘change of heart’?
This is the question.

Got around doing a little video summary, but the devil is in the details below.

“At the age of 89 (August 18, 1932 – February 8, 2022), Professor Luc Montagnier died at the American Hospital in Neuilly-sur-Seine. Doctor Gérard Guillaume, one of his most faithful collaborators, tells us that he left in peace, surrounded by his children.

He was a biologist and virologist, but also and above all a man of remarkable intelligence, who lived for science. In addition to having been named Nobel Prize for Medicine in 2008 for the discovery of the AIDS virus, he worked alongside the greatest scientific institutes in the world during his life. Emeritus research director at the CNRS, professor at the Institut Pasteur, director of the Center for Molecular and Cellular Biology at Queens College of the City University of New York, director of a research institute at the Jiao-tong University of Shanghai. He supported the Academy of Sciences as well as the National Academy of Medicine through his research for many years. For this, he has received countless awards and accolades.

Despite his advanced age and despite all the criticism he suffered in the autumn of his life, notably from part of the scientific community, Luc Montagnier has always fought for free science. We were lucky enough to be able to welcome him several times at FranceSoir, and would like to give him all the honors that are due to him.” – France Soir

He’s just earned his wings

The official announcements say he died in peace, “surrounded by his youngsters”.

Many call this death ‘sudden’, as in “unforeseen”.

Others. such as myself, have been wondering for long why is he still allowed to roam free and blow the whistle, given his deep involvement with the AIDS scam, his out-spoken anti-Pharmafia stance and, more recently, his total dissidence to the Covid / vaccine narrative.

Rare video from World Health Summit, 2010

“His death took place on Tuesday 8 February, on the same day as the funeral of the Italian biologist Franco Trinca struck down by a very violent and suspicious form of Covid-19 despite being in excellent health and used to take care of himself with a thousand precautions. Trinca had often taken up the complaints of the internationally renowned French scientist who, having worked in the field of vaccines, had denounced the dangers of gene serums based on messenger RNA above all for the risk of creating degenerative brain diseases from prions, as highlighted in our latest investigation.” – VT

OMG OMG!
SOURCE

NO CAUSE OF DEATH PROVIDED



Information surrounding his death are inexistent yet, I’m writing this less than 12h after the official announcement. I will add here anything relevant to it, as much as to why he was a major threat to Pharmafia and the WEF cartel.

UPDATE: Associated Press and thus the global mainstream media finally caught up but still no additional info, just more character assassination rituals.

LAST TIMES HE APPEARED IN PUBLIC:

Four weeks before Montagnier’s death:

“On January 9, Montagnier once again appeared on an international media, the Wall Street Journal, in an editorial titled Omicron makes Biden’s vaccination obligations obsolete, co-signed by American constitutionalist Jed Rubenfeld who another disgraced celebrity: married to Amy Chua, fellow law professor at Yale and author of the world bestseller on the mother tiger, Rubenfeld accused of sexual assaults on female students and suspended by Yale for two years. After the article on the Wsj and before the intervention in Milan, Luc Montagnier appeared last Wednesday in the Luxembourg House of Parliament to support a petition against compulsory vaccination, but his commitment against vaccines began well before the Covid era.” – Italy24 News

So, on January 12, 2022, he concluded his career gloriously participating in THIS INVESTIGATION ON CHILDHOOD COVID VACCINATION BY THE LUXEMBOURG PARLIAMENT

And then…

Three weeks before Montagnier’s death:

January 15th, 2022, at a protest in Milan, Italy:

He seems in pretty good shape to me.

“Luc Montagnier, who in 2009 suggested fighting AIDS with better nutrition, he is experiencing an unexpected return these days, accompanied as always by the American assistant and companion Suzanne McDonnell Long, who was next to him in Milan when he added that it was a crime to give this vaccine to children. As in the past, when Montagnier sold expensive papaya preparations in pharmacies, the problem that the professor does not provide any proof of what he claims. His sentences are not based on any research he has done in recent months or years, but respect for the scientific community is not something that would interest him or his followers.” – Italy24 News

So he almost literally died on the barricades…

Last time I checked…

New evidence, including sworn affidavits from leading experts such as Professor Luc A. Montagnier, has been submitted to the International Criminal Court by lawyers in several countries alleging Government’s across the world and their advisors are complicit in genocide, crimes against humanity and breaches of the Nuremberg Code.Daily Expose

“Attorney Melinda C. Mayne, and Kaira S. McCallum submitted a 27-page ‘Request for Investigation’ to the International Criminal Court (ICC) at The Hague back in April 2021 alleging the UK Government and its advisors were complicit in crimes against humanity in the name of Covid-19.

On the 28th of April 2021, the pair received a formal acknowledgement from the ICC and were assigned a case number – ‘141/21’. Since then the pair have been gathering new evidence to use in their ICC claim and have established connections with lawyers and research scientists from around the world.

A new press release released on the 17th August, which can be viewed here, confirms that the pair have received sworn affidavits from leading experts including research scientist and nuclear cardiologist Dr Richard M. Fleming, the Nobel Laureate virologist Professor Luc  A. Montagnier, and Dr Kevin W. McCairn, a neuroscientist and expert on neurological disease.

Professor Luc A Montagnier, who won a Nobel prize for his work on the HIV virus, claimed in April 2020 that he believed the novel coronavirus was created in a laboratory. Then in May 2021 the expert virologist stated that “Mass vaccinations are a scientific error as well as a medical error. It is an unacceptable mistake. The history books will show that, because it is the vaccination that is creating the variants”.

A new claim has also been submitted to the ICC due to the vast amount of new evidence and information that has come to light in the past few months, and the lawyers say they now have compelling evidence that “the SARS-CoV-2 virus and the Covid-19 ‘vaccines’ are deliberately engineered bioweapons that have been released in two phashes on unsuspecting peoples of the world”.

Attorney Melinda C. Mayne, and Kaira S. McCallum have also confirmed that they have now be joined by lawyers who have filed similar Requests for Investigation to the International Criminal Court, in France, the Czech Republic and Slovakia.

Because of this a letter was sent to the ICC on the 12th August 2021 requesting they all be allowed to submit a joint claim, whilst also submitting preliminary evidence for the allegations common to everyone across the world, and requesting the right to have claims specific to individual countries also investigated by the ICC.” – Daily Expose

They called him a “conspirationist” because he was an early adept of the Chinese lab origin of the virus

KARy MULLIS, THE PCR INVENTOR, DIED JUST A FEW MONTHS BEFORE COVID.
DID MONTAIGNER, THE HIV DISCOVERER, DIE JUST MONTHS BEFORE A BIG AIDS RESURGENCE?

Seven weeks before Montagnier’s death:

Four days before Montagnier’s death:

You’ve seen the increasing media coverage about a new HIV strain, I suppose.

Instead of AIDS, I’d call that, and I’m not the only one, “Vaccine-Induced Auto-Immune Syndrome”, but let’s pretend we go along with the official narrative.

Logically, Montaigner should’ve been the first to summon with the Bat Signal.

That never happened. His death happened.

The day Montagnier died:

This was aired in US on the day Montagnier died.

I think we need a recap. we’ll start here and I will gradually build a picture, come back later:

WUHAN-GATES – 3. “COVID-19 Created in Lab with HIV”. Medicine Nobel confirms Indian Research disclosed by Gospa News

(My excerpts, full story HERE)

Professor Luc Montagnier, Nobel Prize for Medicine 2008, to the microphones of the French podcast, specialized in medicine and health, “Pourquoi Docteur” has torn the veil of silence, has broken the sepulcher of taboos, accrediting the research of the Kusuma School of Biology of New Delhi, withdrawn by the authors but republished worldwide by me on Gospa News and Veterans Today a few days ago and immediately targeted by the skepticism of improvised scientists.

Indian research sensationally withdrawn but recovered by Gospa News

«With my colleague, the biomathematician Jean-Claude Perez, we have carefully analyzed the description of the genome of this Rna virus. We weren’t the first, a group of Indian researchers tried to publish a study showing that the complete genome of this virus that has within the sequences of another virus: that of AIDS. The Indian team retracted after publication. But scientific truth always emerges. The AIDS sequence was inserted into the coronavirus genome to attempt to make the vaccine» said Montagnier.

Luc Montagnier, the French virologist Nobel Prize winner for Medicine in 2008 for his AIDS research

In 7 lines, one of the world’s leading experts in medicine makes “tabula rasa” of somewhat sibylline hypotheses so far promoted by virologists, perhaps even induced by some housekeeper worried about national security in the face of the confirmation of a pandemic capable of causing 120 thousand deaths.

His words carry enormous weight: because in 2008 Montagnier discovered the human immunodeficiency virus HIV as the cause of the AIDS epidemic so much that he won the Nobel Prize for Medicine together with Françoise Barré-Sinoussi and Harald zur Hausen.

«Coronavirus would be a manipulated virus, accidentally released from a Chinese laboratory in Wuhan where the AIDS vaccine was being studied. Professor Luc Montagnier said so» writes the Italian Journalism Agency (AGI), one of the few big media to report the news with prominence.

However, it publishes it with less evidence compared to another article on the statements of the American immunologist Anthony Fauci, director of the American National Institute of Allergy and Infectious Diseases, who persistenly supported the natural origin of the virus.

As we have shown in 12 detailed reports on bio-weapon theory, the United States of America are among the prime suspects, together with China, for this pandemic catastrophe.

It is therefore understandable that the American doctor tries to divert attention from the hypothesis of a pathogen manipulated by bioengineering since the most disturbing experiment was conducted by the biosafety 3 of the Burnett Womack Biohazard center at the Chapell Hill site of the University of North Carolina together with the biosafety laboratory 4 of the Wuhan Institute of Virology.

Not only. The research had been supported by the institute where Fauci works through «grants from the National Institute of Allergy & Infectious Disease and the National Institute of Aging of the United States National Institutes of Health (NIH), the National Natural Science Foundation of China and the USAID-EPT-PREDICT funding from EcoHealth Alliance» as stated in the Abstract published by Nature Medicine published in report no. 9.

The trial led to «building a chimeric CoV with a bat CoV S gene (SHC014) in the backbone of a SARS CoV that has adapted to infect mice (MA15) and is capable of infecting human cells».

Researchers Shan-Lu Liu, Linda J. Saif, Susan R. Weiss and Lishan Su wrote that in a study of February 28, in which, however, they showed some fundamental divergences, equal to 96% for about 5 thousand nucleotides, between that “chimeric” CoronaVirus, that is, created in the laboratory and not existing in nature, and the current real pathogen of the SARS-Cov-2 pandemic, so called from the English acronym of Acute Respiratory Severe Syndrome.

But in the supervirus study conducted primarily in the Chapel Hill laboratories of the University of North Carolina, mention that was also made experiments «similar to those using an HIV-based pseudovirus, prepared as previously described and tested on HeLa cells (Wuhan Institute of Virology) which the ACE2 orthologists expressed».

Despite the difference between Covid-19 and the chimeric supervirus, nothing prevents us from thinking that this “prototype” it was then further modified in one of the US Pentagon’s 25 military laboratories, where highly top-secret projects are also managed directly by the Central Intelligence Agency or in one of the 11 existing in the US territory only (on which we will write shortly), including the National Biodefense Analysis and Countermeasures Center – NBACC of the USAMRIID (US Army Medical Institute of Infectious Diseases) in Fort Detrick, Maryland, closed last July for a mysterious biosecurity loss ever better detailed.

http://www.gospanews.net/en/2020/03/24/coronavirus-bioweapon-7-top-secret-military-missions-in-ukraine-fort-detrick-sigonella-wuhan-and-modena/embed/#?secret=YswmTKBpeG

Or that that highly lethal “chimeric supervirus”, such as Covid-19’s “L” genotype, may have been further processed in the Wuhan Virology Institute itself, around which there have been numerous suspicious deaths (of which we will write shortly), concealed by the proverbial Chinese military secrecy imposed by the risk of a capital punishment for espionage or terrorism.

The BSL 4 biosafety labs of the Wuhan Institute of Virology in China

Montagnier is a famous virologist, he was an illustrious professor and researcher of the Pasteur Institute in Paris (one of the first to elaborate a research on the first CoronaVirus strain of SARS in 2003) but for some years he has been working in the most important research center in Shanghai, the Jiao Tong University.

Therefore he is by no means extraneous to matters connected with China and certainly knows Wuhan’s laboratory strongly desired by the entourage of former president Jiang Zemin, historic leader of the Chinese Communist Party who has become popular in the world for international trials for human rights violations in Tibet and for the nickname “executioner of Tiananmen”.

Now Montagnier not only confirms the validity of the Indian study on the traces of HIV inside Covid-19, reported by me in the essential passages from Gospa News and Veterans Today, but supports the “less serious” hypothesis, namely that of an accidental release of the genetically manipulated virus.

Porquoi Docteur’s scoop with the interview with Montagnier

«The hypothesis is that this virus leaves the Wuhan laboratory. It is a high security laboratory but despite all the virus has escaped from the control of the promoters. The history of the fish market is a beautiful legend but it is not possible that it is only a virus transmitted by a bat, it is probably from this that they started, then they modified it. Maybe they wanted to make an AIDS vaccine using a coronavirus as an antigen carrier. A work of sorcerer’s apprentices can be said. Because we must not forget that we are in the world of nature, there are balances to be respected» said Montagnier peremptorily.

According to the scientist, the altered elements of this virus will however be eliminated as it spreads: «Nature does not accept any molecular manipulation, it will eliminate these unnatural changes and even if nothing is done, things will improve, but unfortunately after many deaths».

Also read: AIDS AND COVID ARE TWO COMMERCIAL BRANDS AND ONE BUSINESS MODEL BY FAUCI

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

I failed to make this video viral twice: in November 2020 and the Spring of 2021. Let’s see how it goes now, too late is usually when truth breaks through, and we live from one missed opportunity to the next psyop until we die still waiting for a savior. We could’ve been our own saviors just by paying attention.

Mirror:

Looks like I have to stress one thing out:

Direct implication: what “authoritative sources” have done so far is not ignorance-based misinformation, but deliberate disinformation.

BONUS:

In case you missed this, it’s the same dude who openly admitted on TED that mRNA jabs re-write the genetic code. At least this one went more viral, but not enough to shut up all the nitwits claiming otherwise.

So no surprise this happened

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

Just a quick heads up as many people hurry to cry “victory!” after recent announcements from UK, France, Czech Republic and even Israel.
I can’t fully be with you due to personal issues, but I don’t want to let you fall in another trap and later disappointment either.

https://www.reuters.com/world/europe/france-unveil-timetable-easing-covid-restrictions-2022-01-20/

Israel: “Finance minister calls for end to Green Pass”

https://www.timesofisrael.com/as-serious-covid-cases-near-500-finance-minister-calls-for-end-to-green-pass/

But…

  • Global leaders have been looking at what 2022 might hold for the COVID-19 pandemic at The Davos Agenda.
  • Speakers addressed questions around vaccine equity, the impact on society and economics and whether it might become endemic.
  • Below are some of the key talking points.

SOURCE: WEF

We’re heading towards the third year of the COVID-19 pandemic, which has disrupted lives and livelihoods across the planet and led to at least 5.5 million deaths around the world.

As the Omicron COVID-19 variant surges in many countries – and indeed saw the deferral of an in-person meeting in Davos – the pandemic has been front of mind for many at The Davos Agenda.

So, where is the virus headed? Here’s what speakers from different sectors have said so far this week.

Tackling the COVID-19 pandemic

Xi Jinping, President of the People’s Republic of China, opened this week by reminding us of the work that’s already been done.

“The international community has fought a tenacious battle,” he said.

The global vaccination drive has played a major role in the progress we’ve made so far, with Richard Hatchett, the CEO of CEPI, reminding us of the work of COVAX.

The vaccine-sharing facility, which CEPI co-leads alongside Gavi and the World Health Organization, delivered its one billionth dose of COVID-19 vaccines over the weekend.

The pandemic has impacted every aspect of our lives, though, Israeli Prime Minister Naftali Bennett reminded us – and that has driven the response in his country.

Endemic or pandemic?

The history of infectious diseases can tell us something about the next stages of the pandemic, Anthony Fauci, the Director of the US National Institute of Allergy and Infectious Diseases, explained.

Endemicity would mean ‘a non-disruptive presence without elimination’, he said. Similar to other cold-weather upper respiratory infections or parainfluenzas, he explained.

We’re not going to eliminate this virus, he said.

FAUCI @ WEF’S DAVOS 2022 (starts 6 min in)

Richard Hatchett said his long-term view is that we should anticipate COVID-19 will behave more like flu.

“It will continue to circulate, it will be around, people will get sick and there will be continual evolution of the virus.”

Mike Ryan, the Executive Director of the WHO’s Health Emergencies Programme, struck a cautionary tone though in the Meeting the Challenge of Vaccine Equity session.

“We won’t end the virus this year,” he said. “We may never end the virus. Pandemic viruses end up becoming part of the ecosystem. What we can end is the public health emergency.”

And, in terms of endemic versus pandemic, he was clear. “Endemic does not mean good,” he said, citing the examples of endemic malaria or endemic HIV which kill 100,000s of people. “Endemic just means it’s here forever.”

“What we need to do is get to low-levels of disease incidence, with maximum vaccination of our populations, so nobody has to die.” That’s the end of the emergency, that’s the end of the pandemic, he concluded.

….

And Svein Tore Holsether, President and Chief Executive Officer, Yara International ASA, told us that a move from shareholder to stakeholder capitalism isn’t just needed, it’s expected, he said.

And, sustainability and environmental concerns will remain paramount – particularly in light of COP26.

Our lifestyles and our throwaway culture have exacerbated the climate challenge, Indian Prime Minister Narendra Modi said on Monday. It’s essential we move towards a circular economy, he explained.?

The next steps

The path is unlikely to be smooth though. Beyond the health challenges discussed above – vaccine equity, for example – hurdles need to be overcome in areas from trust to reform in global systems.

Sharan Burrow, General Secretary of the International Trade Union Confederation, explained more about the issue of trust.

And she wasn’t alone. Speakers at the announcement of the Schwab Foundation for Social Entrepreneurship’s Social Innovators of the Year 2022 award were also clear on the issue of trust.

The global community needs to work together, even more than it has already, speakers from across sessions agreed. This is particularly important to ensure the equitable distribution of vaccines, explained President Xi Jinping.

And reform is needed, whether of global financial systems, or the means by which we can equitably produce and distribute vaccines.

And there it goes… Climate-19 in full swing, as I predicted almost 2 years ago

https://news.yahoo.com/german-leader-champions-tack-climate-135118725.html

Also have you seen this below? Well, consider their hopes for vaccination rates have bee crushed by our resistance, hence the delay and later desperation.

VACCINES MAY ACTUALLY END THE PANDEMIC BY JULY, BUT NOT AS YOU THINK

To be updated, most probably.

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

ORDER

I didn’t mean for this website to go as basic as this, quite the opposite, but apparently there’s still a huge need for basic stuff for basic people.
And we can’t really advance much without covering the basics properly.

Study: Pfizer, GSK, Eli Lilly Topped Military Industry in Defrauding US Govt (2010)

Here’s an older meme that’s basically a sequel to the one above

Based on this testimony:

Now compare my memes against this Pfizer press release: Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study

Not much else to add, besides our motto: “Don’t believe what we say, research what we say!”

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

ORDER

Remember when we were getting banned by their Big Tech lemmings for claiming have this capability? That was fun! 

It’s official: Gattaca is Earth, and Earth is no more. Ground-breaking news:

Published January 10, 2021, by Bloomberg TV.

More info:

Pfizer Deepens Commitment to Genetic-Drug Future

10 Jan 2022 (Bloomberg)

“Pfizer Inc. deepened its commitment to the genetic approach to disease underpinning its Covid-19 vaccine on Monday, striking deals that will give access to three smaller companies’ technology in the area.” 

Read more at: https://www.bloombergquint.com/onweb/pfizer-deepens-commitment-to-genetic-drug-future-with-deals

Remember this?

I rest my case.

Also worth checking these older reports:

WE WRITE NEW DNA USING RNA ONLY – STAR SCIENTIST FINANCED BY EPSTEIN, DARPA AND SCHWAB’S WYSS INST.

RNA USED TO ALTER DNA, BRAIN FUNCTIONS AND BEHAVIOR (BIOHACKING P.2)

PFIZER / BIONTECH AND BILL GATES / CHINA ARE LIKE TWO COUPLES OF SWINGERS IN A PERPETUAL ORGY


To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

I so wanted to start the year with some good news rather than more gloom and doom, like most of the data on my hard disks… And we’re damn lucky!

So yeah, Aaron Siri has just announced he won another case against the FDA, the judge correcting the previous abomination about the Pfizer data release. This is the announcement from his Substack:

INSTEAD OF FDA’S REQUESTED 500 PAGES PER MONTH, COURT ORDERS FDA TO PRODUCE PFIZER COVID-19 DATA AT RATE OF 55,000 PAGES PER MONTH!

A great win for transparency that removes a stranglehold “health” authorities have had on data independent scientists need to offer solutions and address serious issues with the vaccine program.

Aaron Siri1 hr ago267110

On behalf of a client, my firm requested that the FDA produce all the data submitted by Pfizer to license its Covid-19 vaccine.  The FDA asked the Court for permission to only be required to produce at a rate of 500 pages per month, which would have taken over 75 years to produce all the documents. 

I am pleased to report that a federal judge soundly rejected the FDA’s request and ordered the FDA to produce all the data at a clip of 55,000 pages per month!

This is a great win for transparency and removes one of the strangleholds federal “health” authorities have had on the data needed for independent scientists to offer solutions and address serious issues with the current vaccine program – issues which include waning immunity, variants evading vaccine immunity, and, as the CDC has confirmed, that the vaccines do not prevent transmission.

No person should ever be coerced to engage in an unwanted medical procedure.  And while it is bad enough the government violated this basic liberty right by mandating the Covid-19 vaccine, the government also wanted to hide the data by waiting to fully produce what it relied upon to license this product until almost every American alive today is dead.  That form of governance is destructive to liberty and antithetical to the openness required in a democratic society. 

In ordering the release of the documents in a timely manner, the Judge recognized that the release of this data is of paramount public importance and should be one of the FDA’s highest priorities.  He then aptly quoted James Madison as saying a “popular Government, without popular information, or the means of acquiring it, is but a Prologue to a Farce or a Tragedy” and John F. Kennedy as explaining that a “nation that is afraid to let its people judge the truth and falsehood in an open market is a nation that is afraid of its people.” 

The following is the full text of the Judge’s order, a copy of which is also available here.

UNITED STATES DISTRICT COURT

PHMPT, Plaintiff v. FDA, Defendant, No. 4:21-cv-1058-P

ORDER

This case involves the Freedom of Information Act (“FOIA”). Specifically, at issue is Plaintiff’s FOIA request seeking “[a]ll data and information for the Pfizer Vaccine enumerated in 21 C.F.R. § 601.51(e) with the exception of publicly available reports on the Vaccine Adverse Events Reporting System” from the Food and Drug Administration (“FDA”). See ECF No. 1. As has become standard, the Parties failed to agree to a mutually acceptable production schedule; instead, they submitted dueling production schedules for this Court’s consideration. Accordingly, the Court held a conference with the Parties to determine an appropriate production schedule.[1] See ECF Nos. 21, 34.

“Open government is fundamentally an American issue” – it is neither a Republican nor a Democrat issue.[2] As James Madison wrote, “[a] popular Government, without popular information, or the means of acquiring it, is but a Prologue to a Farce or a Tragedy; or, perhaps, both. Knowledge will forever govern ignorance: And a people who mean to be their own Governors, must arm themselves with the power which knowledge gives.”[3] John F. Kennedy likewise recognized that “a nation that is afraid to let its people judge the truth and falsehood in an open market is a nation that is afraid of its people.”[4] And, particularly appropriate in this case, John McCain (correctly) noted that “[e]xcessive administrative secrecy . . . feeds conspiracy theories and reduces the public’s confidence in the government.”[5]

Echoing these sentiments, “[t]he basic purpose of FOIA is to ensure an informed citizenry, [which is] vital to the functioning of a democratic society.” NLRB v. Robbins Tire & Rubber Co., 437 U.S. 214, 242 (1977). “FOIA was [therefore] enacted to ‘pierce the veil of administrative secrecy and to open agency action to the light of public scrutiny.’” Batton v. Evers, 598 F.3d 169, 175 (5th Cir. 2010) (quoting Dep’t of the Air Force v. Rose, 425 U.S. 352, 361 (1976)). And “Congress has long recognized that ‘information is often useful only if it is timely’ and that, therefore ‘excessive delay by the agency in its response is often tantamount to denial.’” Open Soc’y Just. Initiative v. CIA, 399 F. Supp. 3d 161, 165 (S.D.N.Y. 2019) (quoting H.R. REP. NO. 93-876, at 6271 (1974)). When needed, a court “may use its equitable powers to require an agency to process documents according to a court-imposed timeline.” Clemente v. FBI, 71 F. Supp. 3d 262, 269 (D.D.C. 2014).

Here, the Court recognizes the “unduly burdensome” challenges that this FOIA request may present to the FDA. See generally ECF Nos. 23, 30, 34. But, as expressed at the scheduling conference, there may not be a “more important issue at the Food and Drug Administration . . . than the pandemic, the Pfizer vaccine, getting every American vaccinated, [and] making sure that the American public is assured that this was not [] rush[ed] on behalf of the United States . . . .” ECF No. 34 at 46. Accordingly, the Court concludes that this FOIA request is of paramount public importance.

“[S]tale information is of little value.” Payne Enters., Inc. v. United States, 837 F.2d 486, 494 (D.C. Cir. 1988). The Court, agreeing with this truism, therefore concludes that the expeditious completion of Plaintiff’s request is not only practicable, but necessary. See Bloomberg, L.P. v. FDA, 500 F. Supp. 2d 371, 378 (S.D.N.Y. Aug. 15, 2007) (“[I]t is the compelling need for such public understanding that drives the urgency of the request.”). To that end, the Court further concludes that the production rate, as detailed below, appropriately balances the need for unprecedented urgency in processing this request with the FDA’s concerns regarding the burdens of production. See Halpern v. FBI, 181 F.3d 279, 284–85 (2nd Cir. 1991) (“[FOIA] emphasizes a preference for the fullest possible agency disclosure of such information consistent with a responsible balancing of competing concerns . . . .”).

Accordingly, having considered the Parties’ arguments, filings in support, and the applicable law, the Court ORDERS that:

1. The FDA shall produce the “more than 12,000 pages” articulated in its own proposal, see ECF No. 29 at 24, on or before January 31, 2022.

2. The FDA shall produce the remaining documents at a rate of 55,000 pages every 30 days, with the first production being due on or before March 1, 2022, until production is complete.

3. To the extent the FDA asserts any privilege, exemption, or exclusion as to any responsive record or portion thereof, FDA shall, concurrent with each production required by this Order, produce a redacted version of the record, redacting only those portions as to which privilege, exemption, or exclusion is asserted.

4. The Parties shall submit a Joint Status Report detailing the progress of the rolling production by April 1, 2022, and every 90 days thereafter.[6]

SO ORDERED on this 6th day of January, 2022.


[1] Surprisingly, the FDA did not send an agency representative to the scheduling conference.

[2] 151 CONG. REC. S1521 (daily ed. Feb. 16, 2005) (statement of Sen. John Cornyn).

[3] Letter from James Madison to W.T. Barry (August 4, 1822), in 9 WRITINGS OF JAMES MADISON 103 (S. Hunt ed., 1910).

[4] John F. Kennedy, Remarks on the 20th Anniversary of the Voice of America (Feb. 26, 1962).

[5] America After 9/11: Freedom Preserved or Freedom Lost?: Hearing Before the S. Comm. on the Judiciary, 108th Cong. 302 (2003).

[6] Although the Court does not decide whether the FDA correctly denied Plaintiff’s request for expedited processing, the issue is not moot. Should the Parties seek to file motions for summary judgment, the Court will take up the issue then.

To be continued?
Our work and existence, as media and people, is funded solely by our most generous readers and we want to keep this way.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them